These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27270155)

  • 1. Accessing the cure: helping patients with hepatitis C overcome barriers to care.
    Rodriguez C; Reynolds A
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s108-12. PubMed ID: 27270155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. It's time to end insurance restrictions on life-saving hepatitis C treatments.
    Clary R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP185-7. PubMed ID: 27266946
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
    Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
    Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/HCV Co-infection: Overcoming Barriers to Treatment.
    Gross C; Akoth E; Price A; Kattakuzhy S; Silk R; Rosenthal E
    J Assoc Nurses AIDS Care; 2016; 27(4):524-9. PubMed ID: 26996983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009.
    Gheorghe L; Pascu O; Ceausu E; Csiki IE; Iacob S; Caruntu F; Simionov I; Vadan R
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):161-7. PubMed ID: 20593049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
    Girardin F; Goossens N; Vernaz N; Negro F
    Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.
    Trooskin SB; Reynolds H; Kostman JR
    Clin Infect Dis; 2015 Dec; 61(12):1825-30. PubMed ID: 26270682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C: An Eastern Perspective.
    Dan YY; Lim SG
    Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--the new and evolving standards of care.
    Owens GM
    Am J Manag Care; 2015 Mar; 21(5 Suppl):S97-105. PubMed ID: 26167959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
    Wei L; Li J; Yang X; Wang G; Feng B; Hou J; Duan Z; Jia J; Ren H; Niu J; Chen X; Wang FS; Shang J; Bo Q; Li R; Liu Y; Zhuang H
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1995-2003. PubMed ID: 27043040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Cost and Value in Hepatitis C Therapy.
    Linas BP
    Top Antivir Med; 2016; 24(2):93-97. PubMed ID: 27841979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.
    Kieran J; Bennett K; Coghlan M; Bergin C; Barry M
    Ir Med J; 2015 Jun; 108(6):166-9. PubMed ID: 26182797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrier to Access or Cost Share? Coinsurance and Dental-Care Utilization in Colombia.
    Higuera L; Prada SI
    Appl Health Econ Health Policy; 2016 Oct; 14(5):569-78. PubMed ID: 27333795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Access to hepatitis C treatment: a lesson for the future.].
    Craxì L
    Recenti Prog Med; 2018 Jan; 109(1):25-27. PubMed ID: 29451518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.